middle.news
Actinogen Medical’s Xanamem Shows Antidepressant Promise in Tough Depression Trial
9:33am on Monday 20th of July, 2026 AEST
•
Biotechnology
Read Story
Actinogen Medical’s Xanamem Shows Antidepressant Promise in Tough Depression Trial
9:33am on Monday 20th of July, 2026 AEST
Key Points
Xanamem demonstrated significant antidepressant activity in difficult-to-treat MDD
Maximal benefit observed at week 10 during blinded follow-up
No correlation between cognitive improvement and depression symptom relief
Trial enrolled 165 participants, many on background SSRI therapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE